Methylphenidate and Pancreatic Enzyme Replacement Therapy

As a result of intensive work, some issues with attention deficit hyperactivity disorder medicines have resolved. All strengths of lisdexamfetamine, atomoxetine capsules, atomoxetine oral solution, and guanfacine prolonged-release tablets are now available.

However, whilst supply of methylphenidate prolonged-release tablets has greatly improved, some issues persist. We are continuing to work to resolve these remaining issues by engaging with all suppliers of methylphenidate prolonged-release tablets and capsules to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to build further capacity to support the continued growth in demand for the short and long-term. The Department is also working with new suppliers of methylphenidate prolonged-release tablets to improve supply and resiliency for the United Kingdom’s market.

The Department is continuing to engage with all suppliers of pancreatic enzyme replacement therapy (PERT) to mitigate the supply issue that is affecting the whole of the UK. Through this, we have managed to secure additional volumes of PERT for 2025 for the UK. We are continuing to work with all suppliers to understand what more can be done to add further resilience to the market. The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market.

In the longer term, the Department has had interest from non-UK suppliers wishing to bring their products to the UK and, along with colleagues in the Medicine and Healthcare products Regulatory Agency, we are working with these potential suppliers, and if authorised, these products could further diversify and strengthen the market.